MediciNova, Inc. (MNOV)

US — Healthcare Sector
Peers: IMUX  FBIO  ACRV  VXRT  RLMD  PMVP  XBIT  TCRX  CBUS  BMEA 

Automate Your Wheel Strategy on MNOV

With Tiblio's Option Bot, you can configure your own wheel strategy including MNOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MNOV
  • Rev/Share 0.0027
  • Book/Share 0.9554
  • PB 1.4759
  • Debt/Equity 0.0064
  • CurrentRatio 13.2634
  • ROIC -0.2799

 

  • MktCap 69155207.0
  • FreeCF/Share -124.2507
  • PFCF -0.0113
  • PE -5.8546
  • Debt/Assets 0.0061
  • DivYield 0
  • ROE -0.2312

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
MNOV
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation.

Read More
image for news MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

About MediciNova, Inc. (MNOV)

  • IPO Date 2006-12-08
  • Website https://www.medicinova.com
  • Industry Biotechnology
  • CEO Yuichi Iwaki
  • Employees 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.